Boston Common Asset Management LLC Sells 55,392 Shares of Edwards Lifesciences Co. (NYSE:EW)

Boston Common Asset Management LLC lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 26.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 152,532 shares of the medical research company's stock after selling 55,392 shares during the period. Boston Common Asset Management LLC's holdings in Edwards Lifesciences were worth $11,292,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. JFS Wealth Advisors LLC boosted its position in Edwards Lifesciences by 31.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company's stock worth $46,000 after acquiring an additional 166 shares during the period. Seascape Capital Management lifted its holdings in Edwards Lifesciences by 0.5% in the third quarter. Seascape Capital Management now owns 32,989 shares of the medical research company's stock worth $2,177,000 after purchasing an additional 174 shares during the period. Cooper Financial Group grew its position in Edwards Lifesciences by 2.8% in the 4th quarter. Cooper Financial Group now owns 6,466 shares of the medical research company's stock valued at $479,000 after buying an additional 175 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. increased its stake in Edwards Lifesciences by 1.2% during the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company's stock valued at $1,417,000 after buying an additional 184 shares during the period. Finally, Martin Capital Advisors LLP raised its position in shares of Edwards Lifesciences by 0.7% during the 3rd quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company's stock worth $1,686,000 after buying an additional 186 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on EW. Royal Bank of Canada increased their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company an "outperform" rating in a report on Thursday, December 5th. Stifel Nicolaus increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company a "hold" rating in a research note on Thursday, December 5th. Daiwa America downgraded Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 30th. Barclays upped their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company an "overweight" rating in a report on Monday, December 2nd. Finally, Citigroup lifted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of "Hold" and an average target price of $78.48.

Edwards Lifesciences Stock Down 0.1 %

Shares of EW stock traded down $0.09 during trading on Friday, hitting $69.77. 5,031,232 shares of the company were exchanged, compared to its average volume of 4,364,863. The business's 50-day simple moving average is $72.06 and its 200 day simple moving average is $71.45. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market capitalization of $41.15 billion, a price-to-earnings ratio of 10.07, a P/E/G ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the previous year, the company earned $0.59 EPS. The firm's revenue was up 8.9% on a year-over-year basis. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the business's stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now owns 198,526 shares of the company's stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of the firm's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock worth $2,195,180 over the last three months. Corporate insiders own 1.27% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.